LOS ANGELES, Feb. 21, 2025 /PRNewswire/ --B.
Riley Securities, Inc. ("B. Riley"), a preeminent middle market
investment bank, will be hosting its Precision Oncology & Radiopharma
Investor Conference on Friday, February 28th in New York.
This one-day conference will
feature more than 30 institutionally relevant companies developing and
commercializing next-gen targeted oncology and radiopharmaceutical therapeutics
and diagnostics. In addition to investor discussions, B. Riley Equity Research
Analysts will be moderating panels covering topics including recent disruptions
to healthcare policy, the evolving radiopharma value chain, antibody drug
conjugates and T-cell engagers, and novel approaches in synthetic lethality.
The emerging modalities being
developed and commercialized by the attending companies have represented an
outsized proportion of recent pharma acquisitions. As the field evolves, this
conference is bringing together industry leaders for early insight into
breakthrough therapies.
Andy Moore, CEO of B. Riley
Securities, commented:
"We're excited to bring together a curated selection of companies at the
forefront of delivering life-saving and critical therapeutic and imaging
modalities. Their pursuits are ground-breaking and create an opportunity for
investors to participate in the next wave of advancement in healthcare."
The conference will feature a
comprehensive schedule, including research analyst-moderated panels,
presentations, fireside chats and roundtables.
Participation in the conference
is by invitation only. If you are interested in registering for the event,
please email BRSHealthcareEvents@brileyfin.com.
B. Riley Securities, Inc.
B. Riley has served as
a preeminent middle market brokerage and investment banking firm for over 25
years. We provide a full suite of investment banking and capital markets
services to companies, financial sponsors, and institutional investors across
all industry verticals. Investment banking services include initial, secondary
and follow-on offerings, institutional private placements, merger and
acquisition (M&A) advisory, SPACs, corporate restructuring and
recapitalization. Widely recognized for our thematic proprietary equity
research, clients benefit from B. Riley's extensive network, industry
expertise, and proven execution capabilities of our end-to-end financial
services platform. Please see disclosures about B. Riley Securities Research here. The firm is a subsidiary of B. Riley Financial
(Nasdaq: RILY). For more information, visit www.brileysecurities.com.
Contact
press@brileyfin.com
SOURCE B. Riley Financial